MA49278A - Oligonucléotides antisens pour moduler l'expression de htra1 - Google Patents

Oligonucléotides antisens pour moduler l'expression de htra1

Info

Publication number: MA49278A
Authority: MA; Morocco
Prior art keywords: antisen; htra1; oligonucleotides; modulate; expression
Prior art date: 2017-06-01

Application number

MA049278A

Other languages

English (en)

Inventor

Marco Berrera

Andreas Dieckmann

Peter Hagedorn

Heidi Rye Hudlebusch

Roberto Iacone

Susanne Kammler

S Ren Ottosen

Lykke Pedersen

Nchez Rub N Alvarez S

Sindri Traustason

Original Assignee

Hoffmann La Roche

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-06-01

Filing date

2018-05-30

Publication date

2020-04-08

2018-05-30 Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche

2020-04-08 Publication of MA49278A publication Critical patent/MA49278A/fr

Links

101001041393 Homo sapiens Serine protease HTRA1 Proteins 0.000 title 1
108091034117 Oligonucleotide Proteins 0.000 title 1
102100021119 Serine protease HTRA1 Human genes 0.000 title 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/712—Nucleic acids or oligonucleotides having modified sugars, i.e. other than ribose or 2'-deoxyribose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21108—HtrA2 peptidase (3.4.21.108)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/323—Chemical structure of the sugar modified ring structure
- C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/341—Gapmers, i.e. of the type ===---===
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/32—Special delivery means, e.g. tissue-specific

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Genetics & Genomics (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
General Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biotechnology (AREA)
Epidemiology (AREA)
Biophysics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Ophthalmology & Optometry (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)

MA049278A 2017-06-01 2018-05-30 Oligonucléotides antisens pour moduler l'expression de htra1 MA49278A (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP17173964		2017-06-01
EP17209407		2017-12-21
EP17209535		2017-12-21

Publications (1)

Publication Number	Publication Date
MA49278A true MA49278A (fr)	2020-04-08

Family

ID=62245334

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA049278A MA49278A (fr)	2017-06-01	2018-05-30	Oligonucléotides antisens pour moduler l'expression de htra1

Country Status (19)

Country	Link
US (3)	US20190055564A1 (fr)
EP (1)	EP3630976A1 (fr)
JP (1)	JP7169995B2 (fr)
KR (1)	KR20200015608A (fr)
CN (1)	CN110691849A (fr)
AU (1)	AU2018277219A1 (fr)
BR (1)	BR112019025290A2 (fr)
CA (1)	CA3062590A1 (fr)
CL (1)	CL2019003337A1 (fr)
CO (1)	CO2019013317A2 (fr)
CR (1)	CR20190543A (fr)
IL (1)	IL271039A (fr)
MA (1)	MA49278A (fr)
MX (1)	MX2019014187A (fr)
PE (1)	PE20191845A1 (fr)
PH (1)	PH12019502636A1 (fr)
RU (1)	RU2019143004A (fr)
TW (1)	TW201907008A (fr)
WO (1)	WO2018220034A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
MX2018015722A (es)	2016-07-01	2019-05-27	Hoffmann La Roche	Oligonucleotidos antisentido para modular expresion del requisito de alta temperatura a 1 (htra1).
WO2019157531A1 (fr)	2018-02-12	2019-08-15	Ionis Pharmaceuticals, Inc.	Composés modifiés et leurs utilisations
CN116507741A (zh) *	2020-08-20	2023-07-28	基因组评论股份有限公司	年龄相关性黄斑变性诊断用生物标记物及其用途
KR20230095097A (ko) *	2020-10-30	2023-06-28	히데아키 하라	눈 조직 섬유화의 저해에 사용하기 위한 gdf15 조절 물질

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3756313B2 (ja)	1997-03-07	2006-03-15	武今西	新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
JP4236812B2 (ja)	1997-09-12	2009-03-11	エクシコンエ／エス	オリゴヌクレオチド類似体
WO2000008134A2 (fr) *	1998-08-03	2000-02-17	Novartis Ag	SERINE PROTEASE DE HtrA HUMAINE
ES2234563T5 (es)	1999-02-12	2018-01-17	Daiichi Sankyo Company, Limited	Nuevos análogos de nucleósidos y oligonucleótidos
US7053207B2 (en)	1999-05-04	2006-05-30	Exiqon A/S	L-ribo-LNA analogues
US6617442B1 (en)	1999-09-30	2003-09-09	Isis Pharmaceuticals, Inc.	Human Rnase H1 and oligonucleotide compositions thereof
WO2004046160A2 (fr)	2002-11-18	2004-06-03	Santaris Pharma A/S	Conception antisens
EP2462937A1 (fr) *	2005-05-24	2012-06-13	Isis Pharmaceuticals, Inc.	Modulation d'expression de LMW-PTPase
WO2007031091A2 (fr)	2005-09-15	2007-03-22	Santaris Pharma A/S	Composes antagonistes d'arn de modulation de l'expression de p21 ras
WO2007090071A2 (fr)	2006-01-27	2007-08-09	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques modifies en position 6
US7666854B2 (en)	2006-05-11	2010-02-23	Isis Pharmaceuticals, Inc.	Bis-modified bicyclic nucleic acid analogs
AU2007249349B2 (en)	2006-05-11	2012-03-08	Isis Pharmaceuticals, Inc.	5'-Modified bicyclic nucleic acid analogs
ES2391788T3 (es) *	2006-07-26	2012-11-29	Yale University, Inc.	Diagnóstico y tratamiento de degeneración macular relacionada con la edad
WO2008067040A2 (fr) *	2006-10-06	2008-06-05	University Of Utah Research Foundation	Procédé de détection de maladies et d'affections pathologiques de l'œil et traitement de celles-ci
CA2688321A1 (fr)	2007-05-30	2008-12-11	Isis Pharmaceuticals, Inc.	Analogues d'acides nucleiques bicycliques pontes par aminomethylene n-substitue
DK2173760T4 (en)	2007-06-08	2016-02-08	Isis Pharmaceuticals Inc	Carbocyclic bicyclic nukleinsyreanaloge
TW200911290A (en)	2007-07-02	2009-03-16	Alcon Res Ltd	RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
AU2008272918B2 (en)	2007-07-05	2012-09-13	Isis Pharmaceuticals, Inc.	6-disubstituted bicyclic nucleic acid analogs
WO2009059321A2 (fr) *	2007-11-01	2009-05-07	University Of Iowa Research Foundation	Analyse de lieu de rca pour estimer la sensibilité à l'amd et au mpgnii
WO2009067647A1 (fr)	2007-11-21	2009-05-28	Isis Pharmaceuticals, Inc.	Analogues d'acide nucléique alpha-l-bicyclique carbocyclique
DK2356129T3 (da)	2008-09-24	2013-05-13	Isis Pharmaceuticals Inc	Substituerede alpha-L-bicykliske nukleosider
US9012421B2 (en)	2009-08-06	2015-04-21	Isis Pharmaceuticals, Inc.	Bicyclic cyclohexose nucleic acid analogs
EP2580228B1 (fr)	2010-06-08	2016-03-23	Ionis Pharmaceuticals, Inc.	2' amino- et 2' thio-nucléosides bicycliques substitués et composés oligomères préparés à partir de ces derniers
FR2965278B1 (fr) *	2010-09-23	2014-10-10	Univ Caen Basse Normandie	Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
EP2753631A1 (fr)	2011-09-07	2014-07-16	Marina Biotech, Inc.	Synthèse et utilisations de composés acides nucléiques comportant des monomères restreints de point de vue conformationnel
EP2850092B1 (fr)	2012-04-09	2017-03-01	Ionis Pharmaceuticals, Inc.	Analogues tricycliques d'acide nucléique
US20150141320A1 (en) *	2012-05-16	2015-05-21	Rana Therapeutics, Inc.	Compositions and methods for modulating gene expression
CN104837996A (zh)	2012-11-15	2015-08-12	罗氏创新中心哥本哈根有限公司	抗apob反义缀合物化合物
US20190284621A1 (en) *	2016-11-11	2019-09-19	Roche Innovation Center Copenhagen A/S	Therapeutic oligonucleotides capture and detection

2018
- 2018-05-29 US US15/991,326 patent/US20190055564A1/en not_active Abandoned
- 2018-05-30 CN CN201880036053.5A patent/CN110691849A/zh active Pending
- 2018-05-30 EP EP18727310.7A patent/EP3630976A1/fr not_active Withdrawn
- 2018-05-30 MX MX2019014187A patent/MX2019014187A/es unknown
- 2018-05-30 PE PE2019002473A patent/PE20191845A1/es unknown
- 2018-05-30 BR BR112019025290-8A patent/BR112019025290A2/pt not_active Application Discontinuation
- 2018-05-30 RU RU2019143004A patent/RU2019143004A/ru unknown
- 2018-05-30 KR KR1020197038723A patent/KR20200015608A/ko not_active Withdrawn
- 2018-05-30 JP JP2019566236A patent/JP7169995B2/ja active Active
- 2018-05-30 WO PCT/EP2018/064221 patent/WO2018220034A1/fr not_active Ceased
- 2018-05-30 CA CA3062590A patent/CA3062590A1/fr not_active Abandoned
- 2018-05-30 CR CR20190543A patent/CR20190543A/es unknown
- 2018-05-30 MA MA049278A patent/MA49278A/fr unknown
- 2018-05-30 AU AU2018277219A patent/AU2018277219A1/en not_active Abandoned
- 2018-05-31 TW TW107118609A patent/TW201907008A/zh unknown
2019
- 2019-10-28 US US16/665,317 patent/US20200157546A1/en not_active Abandoned
- 2019-11-20 CL CL2019003337A patent/CL2019003337A1/es unknown
- 2019-11-22 PH PH12019502636A patent/PH12019502636A1/en unknown
- 2019-11-27 CO CONC2019/0013317A patent/CO2019013317A2/es unknown
- 2019-11-28 IL IL271039A patent/IL271039A/en unknown
2021
- 2021-08-17 US US17/404,989 patent/US20220042022A1/en not_active Abandoned

Also Published As

Publication number	Publication date
TW201907008A (zh)	2019-02-16
CL2019003337A1 (es)	2020-05-15
CO2019013317A2 (es)	2020-01-17
RU2019143004A (ru)	2021-07-09
CN110691849A (zh)	2020-01-14
MX2019014187A (es)	2020-01-27
PH12019502636A1 (en)	2020-06-08
CR20190543A (es)	2020-02-10
PE20191845A1 (es)	2019-12-31
CA3062590A1 (fr)	2018-12-06
WO2018220034A1 (fr)	2018-12-06
JP7169995B2 (ja)	2022-11-11
KR20200015608A (ko)	2020-02-12
JP2020521491A (ja)	2020-07-27
US20220042022A1 (en)	2022-02-10
US20200157546A1 (en)	2020-05-21
BR112019025290A2 (pt)	2020-06-23
US20190055564A1 (en)	2019-02-21
IL271039A (en)	2020-01-30
AU2018277219A1 (en)	2019-12-19
EP3630976A1 (fr)	2020-04-08

Publication	Publication Date	Title
FR25C1001I2 (fr)	2026-01-02	Compositions d'anticorps pour le traitement de tumeurs
EP3607023C0 (fr)	2023-06-07	Solutions micellaires pour traitement de formations d'hydrocarbures
EP3334499A4 (fr)	2019-04-17	Conjugués bioactifs pour l'administration d'oligonucléotides
EP3679141C0 (fr)	2023-06-07	Méthodes et compositions pour inhiber l'expression de la ldha
MA47719A (fr)	2020-01-15	Esketamine pour le traitement de la dépression
PT3506909T (pt)	2022-08-16	Análogos de 4¿-fosfato e oligonucleótidos compreendendo os mesmos
EP3526328A4 (fr)	2020-05-27	Polythérapie pour l'inhibition de c3
EP3353328A4 (fr)	2019-06-12	Modulateurs de l'expression de kras
EP3431075A4 (fr)	2020-01-22	Forme galénique d'édaravone
IL290449A (en)	2022-04-01	Antibody-mediated neutralization of chikungunya virus
EP3325963A4 (fr)	2019-08-14	Amélioration de l'estimation de globules
EP3853365A4 (fr)	2022-06-08	Modulateurs de l'expression de pnpla3
MA53924A (fr)	2021-08-25	Modulateurs de l'expression d'apol1
IL269735A (en)	2019-11-28	Antisense oligonucleotides for the treatment of stargardt disease
EP3470052A4 (fr)	2020-02-26	Composition cosmétique pour les yeux
MA43570A (fr)	2018-11-14	Thérapie génique pour traiter l'hypercholestérolémie familiale
MA51795A (fr)	2020-12-16	Oligonucléotides pour moduler l'expression de tmem106b
EP3634426A4 (fr)	2021-04-07	Compositions pour le traitement d'une fibrose
EP3397288A4 (fr)	2019-09-11	Méthodes pour diminuer l'expression de l'ataxine-2
EP3541379A4 (fr)	2020-05-27	Compositions pour le traitement de l'hypertension
EP3403655A4 (fr)	2019-08-07	Composition pour augmenter l'expression de pgc-1
MA49278A (fr)	2020-04-08	Oligonucléotides antisens pour moduler l'expression de htra1
MA53474A (fr)	2022-01-05	Distribution de lingettes
EP3424868A4 (fr)	2019-11-20	Mécanisme d'extension/contraction
EP3594345A4 (fr)	2021-05-19	Acide nucléique capable d'inhiber l'expression de masp2